Dystonic Disorders
Acquired and inherited conditions that feature DYSTONIA as a primary manifestation of disease. These disorders are generally divided into generalized dystonias (e.g., dystonia musculorum deformans) and focal dystonias (e.g., writer's cramp). They are also classified by patterns of inheritance and by age of onset.
Subtype terms (2)
More specific conditions that are subtypes of Dystonic Disorders in the MeSH hierarchy.
- Dystonia Musculorum Deformans
- Meige Syndrome
2 drugs (1 approved, 1 experimental)
Drugs by status
Phase 4 trials (1)
Phase 3 trials (1)
Phase 2 trials (3)
Phase 1 trials (1)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (11)
Organization Involved with Phase 3 Indications (9)
Organization Involved with Phase 2 Indications (21)
- ASIS Corporation
- BCN Peptides
- Teva
- National Institutes of Health (NIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Pennsylvania
- Emory University
- Stanford University
- University of South Florida
- University of Southern California
- University of Toronto
- Tel Aviv University
- Vanderbilt University
- Icahn School of Medicine at Mount Sinai
- Taro Pharmaceuticals
- University of Western Ontario
- Dystonia Study Group
- United Cerebral Palsy Foundation
- Dystonia Medical Research Foundation
- Don and Linda Carter Foundation
- Crowley Carter Foundation
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (3)